Enzo Biochem (ENZ) Sets New 12-Month Low at $5.34

Enzo Biochem, Inc. (NYSE:ENZ) reached a new 52-week low during trading on Thursday . The stock traded as low as $5.34 and last traded at $5.37, with a volume of 140047 shares trading hands. The stock had previously closed at $5.49.

Separately, ValuEngine cut shares of Enzo Biochem from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st.

Enzo Biochem (NYSE:ENZ) last issued its quarterly earnings results on Tuesday, June 12th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.04). Enzo Biochem had a negative net margin of 4.12% and a negative return on equity of 6.31%. The business had revenue of $25.63 million during the quarter.

Several institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. increased its stake in shares of Enzo Biochem by 5.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 149,854 shares of the medical research company’s stock worth $1,221,000 after purchasing an additional 7,231 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Enzo Biochem by 3.2% during the 4th quarter. Wells Fargo & Company MN now owns 311,826 shares of the medical research company’s stock worth $2,542,000 after buying an additional 9,754 shares during the period. Highbridge Capital Management LLC boosted its holdings in shares of Enzo Biochem by 50.3% during the 1st quarter. Highbridge Capital Management LLC now owns 38,340 shares of the medical research company’s stock worth $210,000 after buying an additional 12,836 shares during the period. First Light Asset Management LLC boosted its holdings in shares of Enzo Biochem by 5.9% during the 1st quarter. First Light Asset Management LLC now owns 251,002 shares of the medical research company’s stock worth $1,375,000 after buying an additional 13,948 shares during the period. Finally, Stone Ridge Asset Management LLC bought a new stake in shares of Enzo Biochem during the 4th quarter worth about $135,000. Institutional investors own 66.67% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc, an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics.

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply